Abstract
The usefulness of combined 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) in locating suspected recurrence in patients with iodine-negative differentiated thyroid cancer (DTC) was evaluated. Thirty-six patients with DTC and suspected iodine-negative recurrence underwent restaging with FDG-PET/CT. The images of CT, FDG-PET, both modalities viewed side by side (CT+PET), and FDG-PET/CT were evaluated by two physicians separately. Imaging results were correlated with either histology (n = 20) and/or clinical follow-up of at least 36 months. Recurrent disease was diagnosed in 22/36 patients. FDG-PET alone, CT alone, CT+PET, and FDG-PET/CT showed a sensitivity of 82%, 73%, 91%, and 96%, respectively. Specificities were 79%, 71%, 79%, and 100%, respectively. FDG-PET/CT significantly improved specificity compared with CT+PET and resulted in a further treatment modification in 5/36 patients (14%). CT alone was especially sensitive for lung metastases, FDG-PET alone for the remainder of the body. Accurate fusion of functional and morphologic data by FDG-PET/CT improves the staging accuracy of patients with suspected recurrence of iodine-negative DTC. This has an impact on patient management in a substantial number of patients.
Similar content being viewed by others
References
Gilliland FD, Hunt WC, Morris DM et al (1997) Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 79:564–573
Schlumberger MJ (1999) Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 22(11 Suppl):3–7
Maxon HR (1999) Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 43:313–323
Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338:297–306
Frilling A, Gorges R, Tecklenborg K et al (2000) Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 128:1067–1074
Grunwald F, Schomburg A, Bender H et al (1996) Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23:312–319
Stokkel MP, Duchateau CS, Dragoiescu C (2006) The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 50:78–87
Grünwald F, Kalicke T, Feine U et al (1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547–1552
Wang W, Macapinlac H, Larson SM et al (1999) [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291–2302
Scott GC, Meier DA, Dickinson CZ (1995) Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99 m pertechnetate and iodine-131-sodium iodide. J Nucl Med 36:1843–1845
Chung JK, So Y, Lee JS et al (1999) Value of FDG PET in papillary thyroid carcinoma with negative I-131 whole-body scan. J Nucl Med 40:986–992
Feine U, Lietzenmayer R, Hanke JP et al (1996) Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468–1472
Weber WA, Avril N, Schwaiger M (1999) Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 175:356–373
Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939–949
Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H (2006) Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 16:80–87
Wahl RL, Quint LE, Cieslak RD et al (1993) “Anatometabolic” tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 34:1190–1197
Freudenberg LS, Fischer M, Antoch G, Jentzen W, Gutzeit A, Rosenbaum SJ, Bockisch A, Egelhof T (2005) Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract 14:155–160
Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U (2006) Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47:616–624
Zimmer LA, McCook B, Meltzer C, Fukui M, Bascom D, Snyderman C, Townsend DW, Johnson JT (2003) Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 128:178–184
Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, Wahl R, Tufano RP (2005) The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115:237–243
Saab G, Driedger AA, Pavlosky W, McDonald T, Wong CY, Yoo J, Urbain JL (2006) Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 16:267–272
Ong SC, Ng DC, Sundram FX (2005) Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. Singapore Med J 46:297–301
Fleming ID, Cooper JS, Henson DE (eds) (1997) AJCC cancer staging manual. 5th edn. American Joint Committee on Cancer. Lippincott-Raven, Philadelphia
Beyer T, Antoch G, Müller S, Egelhof T, Freudenberg LS, Debatin J, Bockisch A (2004) Protocol considerations for combined PET/CT imaging. J Nucl Med 45(suppl 1):25S–35S
Antoch G, Jentzen W, Freudenberg LS, Stattaus J, Mueller SP, Debatin JF, Bockisch A (2003) Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol 38:784–789
Brown LD, Cai TT, DasGupta A (2001) Interval estimation for a Binomial proportion. Stat Sci 16:101–133
Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, Rampin L, Banti E, Carpi A, Muzzio P, Franchi R (2006) Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 60:409–413
do Rosario PW, de Faria S, Bicalho L et al (2005) Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 24:1385–1389
van den Brekel MW, Stel HV, Castelijns JA et al (1990) Cervical lymph node metastasis: assessment of radiological criteria. Radiology 177:379–384
Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42:1S–93S
Buell U, Wieres FJ, Schneider W, Reinartz P (2004) 18FDG-PET in 733 consecutive patients with or without side-by-side CT evaluation: Analysis of 921 lesions. Nuklearmedizin 43:210–216
Truong MT, Erasmus JJ, Munden RF, Marom EM, Sabloff BS, Gladish GW, Podoloff DA, Macapinlac HA (2004) Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol 183:1127–1132
Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK (2002) Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 29:1393–1398
Rosenbaum SJ, Lind T, Antoch G, Bockisch A (2006) False-positive FDG PET uptake—the role of PET/CT. Eur Radiol 16:1054–1065
Sisson JC, Ackermann RJ, Meyer MA et al (1993) Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 77:1090–1094
Bockisch A, Beyer T, Antoch G, Freudenberg LS, Kuhl H, Debatin JF, Muller SP (2004) Positron emission tomography/computed tomography-imaging protocols, artifacts, and pitfalls. Mol Imaging Biol 6:188–199
Kassenärztliche Bundesvereinigung: Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über Kriterien zur Qualitätsbeurteilung in der radiologischen Diagnostik gemäß § 136 SGB V in der Fassung vom 17. Juni 1992 (veröffentlicht im Bundesanzeiger Nr. 183 b vom 29. September 1992), zuletzt geändert am 17. Dezember 1996 (veröffentlicht im Bundesanzeiger Nr. 49 vom 12. März 1997). Deutsches Ärzteblatt 1997; 94, A779–A787
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Freudenberg, L.S., Frilling, A., Kühl, H. et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 17, 3139–3147 (2007). https://doi.org/10.1007/s00330-007-0682-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-007-0682-2